Kumitaa Theva Das
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kumitaa Theva Das has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
V. Kalidasan
Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Pulau Pinang, Malaysia
5 shared publications- Azali Azlan
Department of Cell Biology Johns Hopkins University School of Medicine
2 shared publications Cheng Heng Wong
2 shared publications- Ghows Azzam
School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia
2 shared publications - Kalidasan Vasodavan
Department of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Malaysia
2 shared publications Matthew Tze Jian Wong
2 shared publications
Latest Publications
- 16 November 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (12)
Characterization, Safety and Functional Assessment Of Silver Nanoparticle-Mediated CRISPR/Cas9 Against HIV
- 16 November 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (12)
Characterization, Safety and Functional Assessment Of Silver Nanoparticle-Mediated CRISPR/Cas9 Against HIV
- 7 August 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (8)
In Vivo Safety Evaluation of Silver Nanoparticle Encapsulated CRISPR/Cas9: Implications for HIV Gene Therapy
- 7 August 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (8)
In Vivo Safety Evaluation of Silver Nanoparticle Encapsulated CRISPR/Cas9: Implications for HIV Gene Therapy
- 13 June 2026
- Published by Springer Nature in Mammalian Genome
- Vol. 37 (1)
The evolution of AI-integrated genome editing and its challenges
Artificial Intelligence (AI) is poised to revolutionize the field of genome editing by enhancing precision, efficiency, and accessibility. AI-driven approaches are already improving the design of CRISPR-based systems by enabling more accurate identification of target sequences and predicting off-target effects. Machine learning (ML) algorithms can analyze vast genomic data, as well as identify patterns and mutations that might be overlooked by traditional methods. Taking together, utilizing AI/ML tools allow for the enhancement of every step in genome editing. Recent advances also demonstrated that AI-powered tools can facilitate the simulation and modeling of genetic modifications, predicting their effects on cellular behavior and phenotypes. This allows for a more rapid prediction of the genome editing effects, without the need for wet lab. Additionally, AI can accelerate drug discovery and therapeutic development by streamlining the identification of genetic targets and optimizing gene therapies. The integration of AI with genome editing promises to democratize access to cutting-edge technologies, enabling researchers to design and plan for complex genetic modifications with minimal technical expertise. Drawing from various examples, this paper dives into the advancements and applications of AI in genome editing, its limitations, as well as future directions and opportunities in this field.
- 13 June 2026
- Published by Springer Nature in Mammalian Genome
- Vol. 37 (1)
The evolution of AI-integrated genome editing and its challenges
Artificial Intelligence (AI) is poised to revolutionize the field of genome editing by enhancing precision, efficiency, and accessibility. AI-driven approaches are already improving the design of CRISPR-based systems by enabling more accurate identification of target sequences and predicting off-target effects. Machine learning (ML) algorithms can analyze vast genomic data, as well as identify patterns and mutations that might be overlooked by traditional methods. Taking together, utilizing AI/ML tools allow for the enhancement of every step in genome editing. Recent advances also demonstrated that AI-powered tools can facilitate the simulation and modeling of genetic modifications, predicting their effects on cellular behavior and phenotypes. This allows for a more rapid prediction of the genome editing effects, without the need for wet lab. Additionally, AI can accelerate drug discovery and therapeutic development by streamlining the identification of genetic targets and optimizing gene therapies. The integration of AI with genome editing promises to democratize access to cutting-edge technologies, enabling researchers to design and plan for complex genetic modifications with minimal technical expertise. Drawing from various examples, this paper dives into the advancements and applications of AI in genome editing, its limitations, as well as future directions and opportunities in this field.
- Open Access
- 24 December 2025
- Published by Springer Nature in Virology Journal
- Vol. 23 (1)
Learning from nature: HIV elite controllers as blueprints for a functional cure
Antiretroviral therapy (ART) has transformed HIV infection into a manageable chronic condition but remains non-curative and requires lifelong adherence. Rare cases of long-term remission following stem cell transplantation (SCT) have demonstrated the possibility of viral eradication, yet this approach is not scalable or safe for global implementation. A unique subset of people living with HIV, known as elite controllers (ECs), can naturally suppress replication-competent HIV without ART, often for decades, while maintaining stable CD4 + T cell counts and showing no signs of disease progression. Their ability to sustain treatment-free viral suppression provides compelling evidence that durable remission is biologically achievable, offering a model for cure research. This review synthesizes current evidence on the biology of ECs, encompassing viral, intrinsic antiviral, genetic, and immune mechanisms that underlie natural control. It also examines demographic and clinical characteristics, landmark case reports, and the broader public health implications of elite control. Finally, insights from EC biology are discussed in relation to translational strategies such as gene editing, immune modulation, therapeutic vaccination, and reservoir-targeting approaches designed to mimic or reinforce natural control mechanisms. Understanding the determinants of viral suppression in ECs provides a biological blueprint for the development of a functional cure. As the field advances toward scalable, safe, and durable remission strategies, lessons from ECs remain central to achieving long-term viral control and ultimately ending the HIV epidemic.
- 24 December 2025
- Published by Springer Nature in Virology Journal
- Vol. 23 (1)
Open AccessLearning from nature: HIV elite controllers as blueprints for a functional cure
Antiretroviral therapy (ART) has transformed HIV infection into a manageable chronic condition but remains non-curative and requires lifelong adherence. Rare cases of long-term remission following stem cell transplantation (SCT) have demonstrated the possibility of viral eradication, yet this approach is not scalable or safe for global implementation. A unique subset of people living with HIV, known as elite controllers (ECs), can naturally suppress replication-competent HIV without ART, often for decades, while maintaining stable CD4 + T cell counts and showing no signs of disease progression. Their ability to sustain treatment-free viral suppression provides compelling evidence that durable remission is biologically achievable, offering a model for cure research. This review synthesizes current evidence on the biology of ECs, encompassing viral, intrinsic antiviral, genetic, and immune mechanisms that underlie natural control. It also examines demographic and clinical characteristics, landmark case reports, and the broader public health implications of elite control. Finally, insights from EC biology are discussed in relation to translational strategies such as gene editing, immune modulation, therapeutic vaccination, and reservoir-targeting approaches designed to mimic or reinforce natural control mechanisms. Understanding the determinants of viral suppression in ECs provides a biological blueprint for the development of a functional cure. As the field advances toward scalable, safe, and durable remission strategies, lessons from ECs remain central to achieving long-term viral control and ultimately ending the HIV epidemic.
- Open Access
- 13 September 2025
- Published by Elsevier in The Microbe
- Vol. 9
CRISPR-mediated inhibition of cytomegalovirus viral replication and gene expression as a potential therapeutic approach
- 13 September 2025
- Published by Elsevier in The Microbe
- Vol. 9
Open AccessCRISPR-mediated inhibition of cytomegalovirus viral replication and gene expression as a potential therapeutic approach
- 27 June 2025
- Published by Springer Nature in Current Clinical Microbiology Reports
- Vol. 12 (1) , 1-15
MPOX: Resilient Strategies in Prevention and Diagnosis
- 27 June 2025
- Published by Springer Nature in Current Clinical Microbiology Reports
- Vol. 12 (1) , 1-15
MPOX: Resilient Strategies in Prevention and Diagnosis
- 26 April 2025
- Published by Springer Nature in Gene Therapy
- p. 1-3
From bench to bedside: the future of stable lentiviral packaging cell lines in gene therapy
- 26 April 2025
- Published by Springer Nature in Gene Therapy
- p. 1-3
From bench to bedside: the future of stable lentiviral packaging cell lines in gene therapy
- Open Access
- 3 January 2025
- Published by Springer Nature in Epigenetics & Chromatin
- Vol. 18 (1) , 1-12
The role of genetic diversity, epigenetic regulation, and sex-based differences in HIV cure research: a comprehensive review
Despite significant advances in HIV treatment, a definitive cure remains elusive. The first-in-human clinical trial of Excision BioTherapeutics’ CRISPR-based HIV cure, EBT-101, demonstrated safety but failed to prevent viral rebound. These outcomes may result from the interplay of several factors. Growing evidence indicates that intricate epigenetic modifications play a major role in the persistence of HIV latency, presenting a significant barrier to eradication efforts and causing viral rebound after ART discontinuation. Current strategies to purge the latent reservoir involve LRAs that reactivate latent proviruses. However, their clinical success is hindered by the heterogeneity of HIV reservoirs and the virus’s diverse pathways. Additionally, RNA modifications like N6-methyladenosine (m^6 A) methylation influence HIV biology beyond transcriptional control, affect RNA stability, splicing, and translation, which could enhance therapeutic efficacy. The regulatory framework of chromatin dynamics is also key to understanding viral latency and reactivation, such as Vpr’s role in reactivating latent HIV by targeting HDACs. Sex-specific factors were also shown to play an important role with females, showing stronger early immune responses and higher representation among elite controllers. This review addresses the multifaceted challenges of HIV cure research, focusing on genetic diversity, epigenetic regulation, RNA modifications, chromatin remodeling, and sex-specific factors. By integrating insights into these aspects, this paper aims to advance our understanding of HIV cure strategies and highlight directions for future research.
- 3 January 2025
- Published by Springer Nature in Epigenetics & Chromatin
- Vol. 18 (1) , 1-12
Open AccessThe role of genetic diversity, epigenetic regulation, and sex-based differences in HIV cure research: a comprehensive review
Despite significant advances in HIV treatment, a definitive cure remains elusive. The first-in-human clinical trial of Excision BioTherapeutics’ CRISPR-based HIV cure, EBT-101, demonstrated safety but failed to prevent viral rebound. These outcomes may result from the interplay of several factors. Growing evidence indicates that intricate epigenetic modifications play a major role in the persistence of HIV latency, presenting a significant barrier to eradication efforts and causing viral rebound after ART discontinuation. Current strategies to purge the latent reservoir involve LRAs that reactivate latent proviruses. However, their clinical success is hindered by the heterogeneity of HIV reservoirs and the virus’s diverse pathways. Additionally, RNA modifications like N6-methyladenosine (m^6 A) methylation influence HIV biology beyond transcriptional control, affect RNA stability, splicing, and translation, which could enhance therapeutic efficacy. The regulatory framework of chromatin dynamics is also key to understanding viral latency and reactivation, such as Vpr’s role in reactivating latent HIV by targeting HDACs. Sex-specific factors were also shown to play an important role with females, showing stronger early immune responses and higher representation among elite controllers. This review addresses the multifaceted challenges of HIV cure research, focusing on genetic diversity, epigenetic regulation, RNA modifications, chromatin remodeling, and sex-specific factors. By integrating insights into these aspects, this paper aims to advance our understanding of HIV cure strategies and highlight directions for future research.
- 16 January 2024
- Published by SAGE Publications in Human Gene Therapy
- Vol. 35 (1-2) , 9-25
Advancing Precision Medicine with Gene and Cell Therapy in Malaysia: Ethical, Legal, and Social Implications
A new era of gene and cell therapy for treating human diseases has been envisioned for several decades. However, given that the technology can alter any DNA/cell in human beings, it poses specific ethical, legal, and social difficulties in its application. In Malaysia, current bioethics and medical ethics guidelines tackle clinical trials and biomedical research, medical genetic services, and stem cell research/therapy. However, no comprehensive framework and policy is available to cater to ethical gene and cell therapy in the country. Incorporating ethical, legal, and social implications (ELSI) would be crucial to guide the appropriate use of human gene and cell therapy in conjunction with precision medicine. Policy experts, scientists, bioethicists, and public members must debate the associated ELSI and the professional code of conduct while preserving human rights.
- 16 January 2024
- Published by SAGE Publications in Human Gene Therapy
- Vol. 35 (1-2) , 9-25
Advancing Precision Medicine with Gene and Cell Therapy in Malaysia: Ethical, Legal, and Social Implications
A new era of gene and cell therapy for treating human diseases has been envisioned for several decades. However, given that the technology can alter any DNA/cell in human beings, it poses specific ethical, legal, and social difficulties in its application. In Malaysia, current bioethics and medical ethics guidelines tackle clinical trials and biomedical research, medical genetic services, and stem cell research/therapy. However, no comprehensive framework and policy is available to cater to ethical gene and cell therapy in the country. Incorporating ethical, legal, and social implications (ELSI) would be crucial to guide the appropriate use of human gene and cell therapy in conjunction with precision medicine. Policy experts, scientists, bioethicists, and public members must debate the associated ELSI and the professional code of conduct while preserving human rights.